(Q36784813)

16 August 2017

Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation (English)

1 reference

16 August 2017

1 reference

J Tol

1

1 reference

16 August 2017

A Cats

2

1 reference

16 August 2017

L Mol

3

1 reference

16 August 2017

M Koopman

4

1 reference

16 August 2017

M M E M Bos

5

1 reference

16 August 2017

J J M van der Hoeven

6

1 reference

16 August 2017

N F Antonini

7

1 reference

16 August 2017

J H J M van Krieken

8

1 reference

16 August 2017

C J A Punt

9

1 reference

16 August 2017

12 March 2008

1 reference

Investigational New Drugs

16 August 2017

1 reference

16 August 2017

26

1 reference

16 August 2017

4

1 reference

16 August 2017

393-397

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-008-9125-4

16 August 2017

0 references

cites work

Gastrointestinal perforation due to bevacizumab in colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2480515

Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2480515

Cellular and molecular mechanisms of gastrointestinal ulcer healing

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2480515

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2480515

Gastric mucosal protection: from prostaglandins to gene-therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2480515

New options and old dilemmas in the treatment of patients with advanced colorectal cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2480515

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2480515

Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2480515

The biology of VEGF and its receptors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2480515

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2480515

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2480515

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2480515

Dynamics of changes in vascular endothelial growth factor (VEGF) expression and angiogenesis in stress-induced gastric ulceration in rats

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2480515

A possible defensive mechanism in the basal region of gastric mucosa and the healing of erosions

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2480515

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2480515

4 December 2018

1 reference

12 December 2020

Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?

1 reference

PubMed

12 December 2020

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

1 reference

PubMed

12 December 2020

Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication

1 reference

PubMed

12 December 2020

10.1007/S10637-008-9125-4

Identifiers

DOI

1 reference

16 August 2017

1 reference

16 August 2017

PubMed publication ID

18335169

1 reference